Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at Royal Bank of Canada
Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at Royal Bank of Canada
Royal Bank of Canada assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a report published on Friday morning, The Fly reports. The firm issued an outperform rating and a $23.00 price objective on the biopharmaceutical company's stock.
加拿大皇家銀行承擔對股份的覆蓋 馬里努斯製藥 (納斯達克:MRNS — 獲得評級) 在星期五早上發表的報告中，《飛行》報告。該公司對該生物製藥公司的股票發出了「跑贏大市」評級和 23.00 美元的價格目標。
A number of other equities research analysts have also recently weighed in on the company. HC Wainwright restated a buy rating and issued a $27.00 price target on shares of Marinus Pharmaceuticals in a report on Friday, January 6th. StockNews.com upgraded Marinus Pharmaceuticals from a sell rating to a hold rating in a report on Monday, November 14th. Finally, Robert W. Baird lowered their target price on Marinus Pharmaceuticals from $32.00 to $24.00 and set an outperform rating on the stock in a report on Wednesday, November 9th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Marinus Pharmaceuticals presently has an average rating of Moderate Buy and a consensus price target of $28.13.
該公司最近還有一些其他股票研究分析師對該公司進行了評量。韋賴特在 1 月 6 日（星期五）的一份報告中，HC 溫賴特重申了買入評級，並對馬里努斯製藥的股票發布了 27.00 美元的目標價格。在 11 月 14 日星期一的報告中，Stocknews.com 將馬里努斯製藥從銷售評級升級為保持等級。最後，羅伯特 ·W· 貝爾德將馬里努斯製藥的目標價從 32.00 美元降至 24.00 美元，並在 11 月 9 日（星期三）的一份報告中設定了股票的「跑贏大市」評級。一位投資分析師已將該股票評級為持有評級，其中七名則給予該股票的買入評級。根據 MarketBeat.com 的數據，馬里努斯製藥目前的平均評級為「中等購買」，共識價格目標為 28.13 美元。
Marinus Pharmaceuticals Stock Performance
馬里努斯製藥股票表現
MRNS opened at $5.65 on Friday. The stock has a market cap of $210.16 million, a P/E ratio of -12.28 and a beta of 1.10. The company has a debt-to-equity ratio of 0.91, a current ratio of 8.41 and a quick ratio of 8.40. The stock's 50 day simple moving average is $4.42 and its 200 day simple moving average is $5.46. Marinus Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $12.37.
最近來港幣五元六十五元於星期五開市。該股的市值為 210.16 萬美元，市盈率為 -12.28，測試值為 1.10。該公司的債務與權益比率為 0.91，流動比率為 8.41，快速比率為 8.40。該股票的 50 天簡單移動平均線為 4.42 美元，其 200 日簡單移動平均線為 5.46 美元。馬里努斯製藥有 1 年低點 3.46 美元和 1 年高點 12.37 美元。
Institutional Inflows and Outflows
機構流入和流出
A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of Marinus Pharmaceuticals by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,691,370 shares of the biopharmaceutical company's stock worth $11,248,000 after purchasing an additional 16,812 shares during the period. BlackRock Inc. lifted its stake in shares of Marinus Pharmaceuticals by 1.9% during the 3rd quarter. BlackRock Inc. now owns 959,198 shares of the biopharmaceutical company's stock worth $6,379,000 after purchasing an additional 17,887 shares during the period. Delphia USA Inc. purchased a new position in shares of Marinus Pharmaceuticals during the 3rd quarter worth $86,000. Renaissance Technologies LLC lifted its stake in shares of Marinus Pharmaceuticals by 23.2% during the 3rd quarter. Renaissance Technologies LLC now owns 193,325 shares of the biopharmaceutical company's stock worth $1,286,000 after purchasing an additional 36,425 shares during the period. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Marinus Pharmaceuticals by 392.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 527,925 shares of the biopharmaceutical company's stock worth $3,511,000 after purchasing an additional 420,802 shares during the period. Hedge funds and other institutional investors own 86.88% of the company's stock.
一些大型投資者最近更改了他們在業務中的頭寸。先鋒集團股份有限公司在第三季度將馬里努斯製藥股份的股份提升了 1.0%。領航集團股份有限公司在期內額外購買 16,812 股股份後，擁有該生物製藥公司股票的 1,691,370 股價值 11,248,000 美元。貝萊德公司在第三季度將其馬里努斯製藥公司股份的股份提升了 1.9％。在此期間，貝萊德公司現在擁有該生物製藥公司的 959,198 股股票，價值 6,379,000 美元。德爾菲亞美國公司在第三季度價值 $86,000 購買了馬里努斯製藥股份的新位置。文藝復興時期技術有限責任公司在馬里努斯製藥的股份通過 23.2％ 在第三季度期間解除了股份。文藝復興技術有限責任公司現在擁有 193,325 股價值 1,286,000 美元的生物製藥公司股票在此期間額外購買 36,425 股股票後。最後, 阿森納貢資產管理股份有限公司在第三季度取消了其在馬里努斯製藥股份的股份 392.8%.艾森納光資產管理股份有限公司在期內額外購買 420,802 股股票後，現在擁有該生物製藥公司股票的 527,925 股股票，價值 3,511,000 美元。對沖基金和其他機構投資者擁有公司股票的 86.88％。
Marinus Pharmaceuticals Company Profile
馬里努斯製藥公司簡介
(Get Rating)
(取得評分)
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
馬里努斯製藥公司，一家製藥公司，致力於為患有罕見遺傳癲癇和其他癲癇發作障礙的患者開發和商業化產品。它提供 ZTALMY，一種口服懸浮液，用於治療與周期依賴性激酶樣激酶樣 5 缺乏症相關的癲癇發作，適用於急性和慢性護理的成人和兒童患者群體，以及住院和自我管理設置。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Marinus Pharmaceuticals (MRNS)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
- 獲取有關馬里努斯製藥公司（MRNS）的研究報告的免費副本
- 諾斯羅普·格魯曼拋售是一個機會嗎？
- 新的首席執行官在裝甲股票下最糟糕的背後是什麼？
- 微軟對聊天 GBT 的投資對 MSFT 股票意味著什麼？
- 分析師喜歡適合斯凱奇美國
- 我們可以相信標普 500 的反彈
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收馬里努斯製藥日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Marinus 製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。